Literature DB >> 27526298

PAX7 Expression in Rhabdomyosarcoma, Related Soft Tissue Tumors, and Small Round Blue Cell Neoplasms.

Gregory W Charville1, Sushama Varma, Erna Forgó, Sarah N Dumont, Eduardo Zambrano, Jonathan C Trent, Alexander J Lazar, Matt van de Rijn.   

Abstract

Rhabdomyosarcoma, the most common soft tissue malignancy of childhood, is a morphologically variable tumor defined by its phenotype of skeletal muscle differentiation. The diagnosis of rhabdomyosarcoma often relies in part on the identification of myogenic gene expression using immunohistochemical or molecular techniques. However, these techniques show imperfect sensitivity and specificity, particularly in scant tissue biopsies. Here, we expand the toolkit for rhabdomyosarcoma diagnosis by studying the expression of PAX7, a transcriptional regulator of mammalian muscle progenitor cells implicated in the pathogenesis of rhabdomyosarcoma. Immunohistochemical analysis of tissue microarrays using a monoclonal anti-PAX7 antibody was used to characterize PAX7 expression in 25 non-neoplastic tissues, 109 rhabdomyosarcomas, and 697 small round blue cell or other soft tissue tumors. Among non-neoplastic tissues, PAX7 was specifically expressed in adult muscle progenitor cells (satellite cells). In embryonal rhabdomyosarcoma, PAX7 expression was positive in 52 of 63 cases (83%), negative in 9 of 63 cases (14%), and focal in 2 of 63 cases (3%). PAX7-positive embryonal rhabdomyosarcoma cases included several showing focal or negative myogenin expression. PAX7 expression in alveolar rhabdomyosarcoma was positive in 6 of 31 cases (19%), negative in 14 of 31 cases (45%), and focal in 11 of 31 cases (36%). In addition, PAX7 was expressed in 5 of 7 pleomorphic rhabdomyosarcomas (71%) and 6 of 8 spindle cell rhabdomyosarcomas (75%). Among histologic mimics, only Ewing sarcoma showed PAX7 expression (7/7 cases, 100%). In contrast, expression of PAX7 was not seen in the large majority (688/690, 99.7%) of examined cases of other soft tissue tumors, small round blue cell neoplasms, and leukemias/lymphomas. In summary, immunohistochemical analysis of PAX7 expression may be a useful diagnostic tool in the assessment of skeletal muscle differentiation in human tumors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27526298     DOI: 10.1097/PAS.0000000000000717

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

1.  Immunohistochemistry for PAX7 is a useful confirmatory marker for Ewing sarcoma in decalcified bone marrow core biopsy specimens.

Authors:  Sebastian Fernandez-Pol; Matt van de Rijn; Yasodha Natkunam; Gregory W Charville
Journal:  Virchows Arch       Date:  2018-07-17       Impact factor: 4.064

2.  A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma.

Authors:  Sounak Gupta; Carlos P Sosa; Farhad Kosari; Andrew Folpe; Kaustubh N Bhinge; Lin Yang; Alireza Agahi; Sarah H Johnson; Igor Frank; Stephen A Boorjian; Donna E Hansel; Hikmat A Al-Ahmadie; Victor E Reuter; George Vasmatzis; Rafael E Jimenez; Loren Herrera-Hernandez; John C Cheville
Journal:  Hum Pathol       Date:  2019-04-01       Impact factor: 3.466

3.  EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma.

Authors:  Gregory W Charville; Wei-Lien Wang; Davis R Ingram; Angshumoy Roy; Dafydd Thomas; Rajiv M Patel; Jason L Hornick; Matt van de Rijn; Alexander J Lazar
Journal:  Mod Pathol       Date:  2017-06-23       Impact factor: 7.842

Review 4.  Diagnosis of soft tissue tumors using immunohistochemistry as a surrogate for recurrent fusion oncoproteins.

Authors:  Margaret A Black; Gregory W Charville
Journal:  Semin Diagn Pathol       Date:  2021-11-03       Impact factor: 3.464

5.  The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.

Authors:  Matthew J McBride; John L Pulice; Hannah C Beird; Davis R Ingram; Andrew R D'Avino; Jack F Shern; Gregory W Charville; Jason L Hornick; Robert T Nakayama; Enrique M Garcia-Rivera; Dejka M Araujo; Wei-Lien Wang; Jen-Wei Tsai; Michelle Yeagley; Andrew J Wagner; P Andrew Futreal; Javed Khan; Alexander J Lazar; Cigall Kadoch
Journal:  Cancer Cell       Date:  2018-05-31       Impact factor: 31.743

6.  Single Nuclear RNA Sequencing Highlights Intra-Tumoral Heterogeneity and Tumor Microenvironment Complexity in Testicular Embryonic Rhabdomyosarcoma.

Authors:  Xuezheng Xu; Zhizhong Liu; Yi Li; Liqing Fan; Shuang Wang; Jie Guo; Yanwei Luo; Hao Bo
Journal:  J Inflamm Res       Date:  2022-01-22

7.  Systematic identification of cancer-specific MHC-binding peptides with RAVEN.

Authors:  Michaela C Baldauf; Julia S Gerke; Andreas Kirschner; Franziska Blaeschke; Manuel Effenberger; Kilian Schober; Rebeca Alba Rubio; Takayuki Kanaseki; Merve M Kiran; Marlene Dallmayer; Julian Musa; Nurset Akpolat; Ayse N Akatli; Fernando C Rosman; Özlem Özen; Shintaro Sugita; Tadashi Hasegawa; Haruhiko Sugimura; Daniel Baumhoer; Maximilian M L Knott; Giuseppina Sannino; Aruna Marchetto; Jing Li; Dirk H Busch; Tobias Feuchtinger; Shunya Ohmura; Martin F Orth; Uwe Thiel; Thomas Kirchner; Thomas G P Grünewald
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.